Nanobiotix S.A. showcased a substantial rebound in revenue for fiscal year 2025, driven by contract amendments and ongoing clinical development of its physics-based nanotherapeutics platform. Despite persistent net losses common in clinical-stage biotech, the company improved its liquidity profile with cash reserves of €52.8 million and maintained a current ratio above 1. Its lead candidate, JNJ-1900 (NBTXR3), is undergoing multiple Phase 2/3 trials targeting diverse oncology indications, supported by collaborations with Janssen and MD Anderson Cancer Center. Market attention is heightened by recent share acquisition activities and clarified takeover rumors, with key clinical milestones on the horizon.